immunotherapy / IFN-γ Cancer Research Results

immuno, immunotherapy: Click to Expand ⟱
Features: 
Immunotherapy is not one drug class. It includes:
-Immune checkpoint inhibitors (PD-1, PD-L1, CTLA-4)
-CAR-T therapies
-Monoclonal antibodies
-Cytokine therapies (IL-2, IFN-α)
-Cancer vaccines
-Bispecific T-cell engagers
PD-1 blockade antibody therapy is one of the cornerstone approaches in modern cancer immunotherapy.
Under normal physiological conditions, when PD-1 binds to its ligands (PD-L1 or PD-L2) on other cells, it functions as a "checkpoint" to reduce overly active T cell responses and prevent autoimmunity.
PD-1 blockade therapies involve monoclonal antibodies that target either PD-1 or its ligand PD-L1.
• By blocking the interaction between PD-1 and its ligands, these antibodies effectively release the "brakes" on T cells.
• The re-activated T cells can then recognize and destroy cancer cells more efficiently.

Immunotherapy Class Example Agents Primary Target Core Mechanism Interaction Considerations Net Effect
PD-1 inhibitors Nivolumab, Pembrolizumab PD-1 receptor on T cells Blocks inhibitory PD-1 signaling → restores cytotoxic T-cell activity High-dose steroids or strong immunosuppressants may blunt effect; autoimmune risk ↑ Anti-tumor immune activation
PD-L1 inhibitors Atezolizumab, Durvalumab PD-L1 on tumor/immune cells Prevents PD-L1 from engaging PD-1 → enhances T-cell response Similar immune-related adverse event (irAE) profile as PD-1 inhibitors ↑ Immune activation
CTLA-4 inhibitors Ipilimumab CTLA-4 checkpoint Enhances early T-cell priming in lymph nodes Higher autoimmune toxicity risk vs PD-1 class ↑ T-cell priming
CAR-T therapy CD19 CAR-T products Tumor antigen (e.g., CD19) Genetically engineered T cells directly target tumor cells Risk of cytokine release syndrome (CRS) and neurotoxicity Direct immune-mediated tumor killing
Monoclonal antibodies (non-checkpoint) Trastuzumab, Rituximab Specific tumor antigens Antibody-dependent cellular cytotoxicity (ADCC) or receptor blockade Combination with chemo common; immune activation depends on Fc engagement Targeted immune-mediated killing
Cytokine therapy IL-2, IFN-α Immune activation pathways Stimulates T-cell and NK cell proliferation High systemic toxicity; rarely used now vs checkpoint inhibitors Broad immune stimulation
Cancer vaccines mRNA or peptide-based Tumor antigens Induces tumor-specific immune memory Often combined with checkpoint blockade Adaptive immune priming
Bispecific T-cell engagers Blinatumomab CD3 + tumor antigen Bridges T cells directly to tumor cells CRS risk; continuous infusion in some protocols Direct T-cell redirection


IFN-γ, Interferon-γ: Click to Expand ⟱
Source:
Type:
Plays a key role in activation of cellular immunity and subsequently, stimulation of antitumor immune-response. Based on its cytostatic, pro-apoptotic and antiproliferative functions, IFN-γ is considered potentially useful for adjuvant immunotherapy for different types of cancer.
Moreover, it IFN-γ may inhibit angiogenesis in tumor tissue, induce regulatory T-cell apoptosis, and/or stimulate the activity of M1 proinflammatory macrophages to overcome tumor progression.
However, the current understanding of the roles of IFN-γ in the tumor microenvironment (TME) may be misleading in terms of its clinical application.

IFN-γ is often expressed in the tumor microenvironment, particularly in response to immune cell infiltration. Its expression can be influenced by the presence of tumor-infiltrating lymphocytes (TILs) and other immune cells.
High levels of IFN-γ are typically associated with a Th1 immune response, which is generally considered beneficial for anti-tumor immunity.

Tumor Suppression:
In many cases, IFN-γ has tumor-suppressive effects, as it can inhibit tumor cell proliferation and induce apoptosis in certain cancer types.
Scientific Papers found: Click to Expand⟱
1205- Caff,  immuno,    Caffeine-enhanced anti-tumor activity of anti-PD1 monoclonal antibody
- in-vivo, Melanoma, B16-F10
OS↑, CD4+↑, CD8+↑, AntiTum↑, TNF-α↑, IFN-γ↑,
1283- GA,  immuno,    Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy
- vitro+vivo, CRC, NA
p‑STAT3↓, Treg lymp↓, FOXP3↓, CD8+↑, IFN-γ↑,
1041- Lyco,  immuno,    Lycopene improves the efficiency of anti-PD-1 therapy via activating IFN signaling of lung cancer cells
- in-vivo, Lung, NA
TumVol↓, TumW↓, eff↑, IL1↑, IFN-γ↑, IL4↓, IL10↓,
5602- NaHCO3,  immuno,    Immunotherapy Enhancement by Targeting Extracellular Tumor pH in Triple-Negative Breast Cancer Mouse Model
- in-vivo, BC, 4T1
eff↑, TumCG↓, OS↑, e-pH↑, IFN-γ↑, IL2↑, IL12↑, Dose↝, PD-L1↓,

Showing Research Papers: 1 to 4 of 4

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 4

Pathway results for Effect on Cancer / Diseased Cells:


Proliferation, Differentiation & Cell State ⓘ

p‑STAT3↓, 1,   TumCG↓, 1,  

Migration ⓘ

Treg lymp↓, 1,  

Immune & Inflammatory Signaling ⓘ

CD4+↑, 1,   FOXP3↓, 1,   IFN-γ↑, 4,   IL1↑, 1,   IL10↓, 1,   IL12↑, 1,   IL2↑, 1,   IL4↓, 1,   PD-L1↓, 1,   TNF-α↑, 1,  

Cellular Microenvironment ⓘ

e-pH↑, 1,  

Drug Metabolism & Resistance ⓘ

Dose↝, 1,   eff↑, 2,  

Clinical Biomarkers ⓘ

PD-L1↓, 1,  

Functional Outcomes ⓘ

AntiTum↑, 1,   OS↑, 2,   TumVol↓, 1,   TumW↓, 1,  

Infection & Microbiome ⓘ

CD8+↑, 2,  
Total Targets: 22

Pathway results for Effect on Normal Cells:


Total Targets: 0

Scientific Paper Hit Count for: IFN-γ, Interferon-γ
4 immunotherapy
1 Caffeine
1 Gallic acid
1 Lycopene
1 Bicarbonate(Sodium)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:207  Target#:442  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page